A New Drug Nearly Doubles Survival in Pancreatic Cancer

The drug daraxonrasib (developed by Revolution Medicines) targets the mutated KRAS protein — the main “driving force” behind more than 90% of pancreatic cancer cases. In a study involving 500 patients with metastatic disease, those who received the new drug in combination with chemotherapy lived an average of 13.2 months, compared to just 6.7 months in the control group. The risk of death decreased by approximately 60%.

This represents one of the most significant improvements in survival for this type of cancer in recent years. The drug demonstrated good tolerability, although characteristic side effects were observed (rash, diarrhea, mucosal inflammation).

“We have finally been able to effectively target what for a long time was considered an ‘undruggable’ target,” the study authors noted.

The drug is currently undergoing regulatory review and further study. If the results are confirmed in real‑world clinical practice, this will mark an important breakthrough in the treatment of one of the most aggressive forms of cancer.

Sources

• Christopher Lieu et al. Daraxonrasib in previously treated KRAS-mutated pancreatic cancer. New England Journal of Medicine, 2026.
• Press release, University of Colorado and ScienceDaily (June 6, 2026).